Media Felicia Investor Jennifer
Media Felicia Investor Jennifer Contacts: Bisaro Contacts: Halchak (646) (201) 275-2711 703-1807 Kate Renee Vossen McKnight (732) (551) 675-8448 204-6129
First quarter 2026 · revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency.
First quarter 2026 · diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71.
First · quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%.
On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, “Sun Pharma”) in an all-cash transaction (the “merger”). The merger is expected to close in early 2027, subject to customary closing conditions, including receipt of required regulatory approvals · and approval by Organon stockholders. ──────────────────────────────────────────────────────────────────────────────
In light of the pending · merger, Organon will not be providing financial guidance or hosting quarterly earnings calls.
Totals may not foot due to rounding and percentages are computed using unrounded amounts. (1) Other includes manufacturing sales to third parties.
For the first quarter of 2026, total revenue was $1.460 billion, down 4% on an as-reported basis and down 9% excluding the impact of foreign currency (ex-FX), compared with the first quarter of 2025.
Women’s Health revenue declined 16% as-reported and declined 19% ex-FX in the first quarter of 2026, compared with the first quarter of 2025.
Sales of Nexplanon® (etonogestrel implant) decreased 21% ex-FX in the first quarter compared with the first quarter of 2025. In the U.S., sales of Nexplanon declined 28% primarily due to both – decreased physician demand following the five-year label approval which as expected, has delayed reinsertions; and continued uncertainty around federal funding. Outside of the U.S., Nexplanon sales declined 4% ex-FX, due to the timing of shipments in selective emerging markets, partially offset by increased demand and access in Brazil.
Sales of oral contraceptives MarvelonTM (desogestrel and ethinyl estradiol pill) and MercilonTM (desogestrel and ethinyl – estradiol pill) declined 36% ex-FX in the first quarter of 2026 primarily due to decreased demand and market contraction in China and the timing of shipments in Asia Pacific.
Global Fertility revenue was down 9% ex-FX as a result of – competition-driven price reductions in the U.S. partially offset by modest market growth in China.
– In January of 2026 the company completed the sale of the Jada® system to Laborie.
2 Biosimilars revenue increased23% as-reported and 21% ex-FX in the first quarter of 2026, compared with the first quarter of2025, primarily due to the strong performance of Hadlima® (adalimumab-bwwd) associated with stronger demand in the U.S., and increased demand in Puerto Rico. Biosimilars also benefitted from contribution from new assets, Bildyos® (denosumab-nxxp) and Bilprevda® (denosumab-nxxp) which were approved by the U.S. Food and Drug Administration (“FDA”) in the third quarter of 2025, and Tofidence® (tocilizumab-bavi), which the company acquired in the second quarter of 2025.
Established Brands revenue declined1% as-reportedand declined 7% ex-FX in the first quarter of 2026.Revenue contribution from Emgality®(galcanezumab-gnlm) partially offset a decline in the respiratory portfolio, which was driven by pricing pressure, as well as volume declines related to the adoption of revised medical guidelines that deprioritize the use of montelukast, including Singulair®(montelukast sodium), in various international markets, most recently, in China. Global sales of Dulera®(mometasone furoate and formoterol fumarate dihydrate) also declined in the first quarter of 2026 primarily due to pricing pressure and decreased demand in the U.S. VTAMA®(tapinarof) grew modestly in the first quarter of 2026 compared with the first quarter of 2025.
(1) Organon acquired certain European licensing and distribution rights to Emgalityfrom Eli Lilly and Company (“Eli Lilly”) beginning in early 2024. Emgalityis a registered trademark of Eli Lilly in the European Union and other countries (used under license). 3 First Quarter 2026 Profitability
(1) See Tables 4 and 5 for reconciliations of GAAP to non-GAAP financial measures.
Reported gross margin in the first quarter of 2026 was 53.6% compared with 55.6% in the prior year period. Non-GAAP Adjusted gross margin was 59.0% in the first quarter of 2026, compared to 61.7% in the first quarter of 2025. Unfavorable pricing and product mix as well as foreign exchange rates were notable drivers in the decline of both reported gross margin and non-GAAP Adjusted gross margin.
Net income for the first quarter of 2026 was $146 million, or $0.55 per diluted share, compared with net income of $87 million, or $0.33 per diluted share, in the first quarter of 2025. For the first quarter of 2026, non-GAAP Adjusted net income was $188 million, or $0.71 per diluted share, compared with $265 million, or $1.02 per diluted share, for the first quarter of 2025. 4 Non-GAAP Adjusted EBITDA margin was 28.4% in the first quarter of 2026 compared with 32.0% in the first quarter of 2025. The year-over-year decline was primarily driven by a decrease in Adjusted Gross Margin.
Today, Organon’s Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on June 11, 2026, to stockholders of record at the close of business on May 11, 2026.
As of March 31, 2026, cash and cash equivalents were $1.12 billion, and debt was $8.57 billion.
As is customary during the pendency of an acquisition, Organon has suspended its quarterly earnings calls and will not host a conference call in conjunction with today’s first quarter earnings release.
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.
Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at http://www.organon.com and follow us on LinkedIn, Instagram, X,YouTube, TikTok and Facebook. 5 Cautionary Note Regarding Non-GAAP Financial Measures
This press release contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are correspondingly not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Specifically, the company makes use of the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, Adjusted gross margin, Adjusted gross profit, Adjusted net income, Adjusted EPS, and Adjusted diluted EPS, which are not recognized terms under GAAP and are presented only as a supplement to the company’s GAAP financial statements. This press release also provides certain measures that exclude the impact of foreign exchange. We calculate foreign exchange by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. The company believes that these non-GAAP financial measures help to enhance an understanding of the company’s financial performance. However, the presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these non-GAAP measures may not be comparable to other similarly titled measures of other companies. Please refer to Table 4 and Table 5 of this press release for additional information, including relevant definitions and reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures.
The company’s management uses the non-GAAP financial measures described above to evaluate the company’s performance and to guide operational and financial decision making. Further, the company’s management believes that these non-GAAP financial measures, which exclude certain items, help to enhance its ability to meaningfully communicate its underlying business performance, financial condition and results of operations.
Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the merger, including the anticipated timing of completion thereof. Forward-looking statements may be identified by words such as “proposed,” “will,” “continue,” “expects,” “believes,” “estimates,” “opportunity,” “pursue,” “anticipate,” “be able to,” “intend,” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. 6 Risks and uncertainties include, but are not limited to uncertainties as to the timing of the merger; the risk that the merger may not be completed on the anticipated terms in a timely manner or at all; the failure to satisfy any of the conditions to the consummation of the merger, including receiving, on a timely basis or otherwise, the minimum vote required by Organon’s stockholders to approve the merger; the possibility that competing offers or acquisition proposals for Organon will be made; the possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive agreement, including in circumstances which would require Organon to pay a termination fee; the effect of the announcement or pendency of the merger on Organon’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; risks related to diverting management’s attention from Organon’s ongoing business operations; the risk that stockholder litigation in connection with the merger may result in significant costs of defense, indemnification and liability; certain restrictions during the pendency of the merger that may impact Organon’s ability to pursue certain business opportunities or strategic transactions; the risk that any announcements relating to the merger could have adverse effects on the market price of Organon’s common stock, including if the merger is not consummated; risks that the benefits of the merger are not realized when and as expected; and legislative, regulatory and economic developments.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the SEC, including the company’s most recent Annual Report on Form 10-K, Current Report on Form 8-K, filed by the company on April 27, 2026, and other SEC filings, available at the SEC’s Internet site (www.sec.gov). 7 Additional Information and Where to Find It
This press release may be deemed to be solicitation material in respect of the proposed merger. In connection with the merger, Organon intends to file relevant materials with the SEC, including Organon’s proxy statement in preliminary and definitive form on Schedule 14A (the “Merger Proxy Statement”). Organon will mail the Merger Proxy Statement and a proxy card to its stockholders in connection with the merger.
INVESTORS AND STOCKHOLDERS OF ORGANON ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE MERGER PROXY STATEMENT (WHEN THEY ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT ORGANON, SUN PHARMA AND THE MERGER AND RELATED MATTERS. Investors and stockholders of Organon are or will be able to obtain these documents (when they are available) free of charge from the SEC’s website at , or through the investor relations section of Organon’s website, .
Organon and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be “participants” in the solicitation of proxies from stockholders of Organon in favor of the proposed acquisition. Information about Organon’s directors and executive officers is set forth in the 2026 Annual Meeting Proxy Statement, filed with the SEC on April 24, 2026, and which is available at . To the extent holdings of Organon’s securities by its directors or executive officers have changed since the amounts set forth in the 2026 Annual Meeting Proxy Statement, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, which are available at . Additional information concerning the interests of Organon’s participants in the solicitation, which may, in some cases, be different than those of Organon’s stockholders generally, will be set forth in the Merger Proxy Statement when it becomes available. 8 TABLE 1 Organon & Co.
Three Months Ended March 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Revenues $ 1,460 $ 1,513 Cost of sales 677 672 Gross Profit 783 841 Selling, general and 424 420 administrative Research and development 93 96 Acquired in-process research and — 6 development and milestones Restructuring costs 31 86 Interest expense 111 124 Exchange losses (gains) 7 (4 ) Other (income) expense, net (96 ) 12 Income before income taxes 213 101 Income tax expense 67 14 Net income $ 146 $ 87 Earnings per share: Basic $ 0.56 $ 0.34 Diluted $ 0.55 $ 0.33 Weighted average shares outstanding: Basic 260,370 257,862 Diluted 262,896 261,001
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies. (1) Includes sales of products not listed separately.
(1) Manufacturing network related costs include costs from exiting manufacturing and supply agreements with Merck & Co., Inc., Rahway NJ, US. For additional details refer to Table 5. (2) Acquisition-related costs relate to costs from the acquisition of Dermavant. For additional details refer to Table 5.
Three Months Ended March 31, 2026 2025 GAAP Gross Margin 53.6 % 55.6 % Total impact of Non-GAAP 5.4 % 6.1 % adjustments Adjusted Non-GAAP Gross Margin 59.0 % 61.7 %
Three Months Ended March 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── GAAP Selling, general $ 424 $ 420 and administrative expenses Adjusted for: Stock-based compensation (13 ) (16 ) Restructuring related charges — (6 ) Other (13 ) (3 ) Adjusted Non-GAAP Selling, general and $ 398 $ 395 administrative expenses
(1) Manufacturing network related costs include costs from exiting manufacturing and supply agreements with Merck & Co., Inc., Rahway NJ, US. For additional details refer to Table 5.
Three Months Ended March 31, 2026 2025 ───────────────────────────────────────────────────────────────────────────── GAAP Reported Net $ 146 $ 87 Income Adjusted for: Cost of sales adjustments 78 93 Selling, general and administrative 26 25 adjustments Research and development adjustments 7 8 Jada divestiture (81 ) — Restructuring 31 86 Change in fair value of contingent (5 ) 11 consideration Other (gain) expense, net (3 ) 4 Tax (11 ) (49 ) impact on adjustments above(1) Non-GAAP Adjusted Net Income $ 188 $ 265
(1) For the three months ended March 31, 2026 and 2025, the GAAP income tax rates were 31.4% and 13.4%, respectively, and the non-GAAP income tax rates were 29.3% and 19.2%, respectively. These adjustments represent the estimated tax impacts on the reconciling items by applying the statutory rate and applicable law of the originating territory of the non-GAAP adjustments.
Three Months Ended March 31, 2026 2025 ─────────────────────────────────────────────────────────────────────────── GAAP Reported Net Income $ 146 $ 87 Depreciation 38 32 (1) Amortization 47 50 Interest expense 111 124 Income tax expense 67 14 (benefit) EBITDA (Non-GAAP) $ 409 $ 307 Restructuring and related charges 31 92 Manufacturing 27 36 network related (2) Acquisition-related 7 9 costs (3) Change in contingent consideration (5 ) 11 Jada divestiture (81 ) — Other costs 8 5 Stock-based compensation 19 24 Adjusted EBITDA (Non-GAAP) $ 415 $ 484 Adjusted EBITDA margin (Non-GAAP) 28.4 % 32.0 %
(2) Manufacturing network related costs, including exiting of temporary manufacturing and supply agreements with Merck & Co., Inc., Rahway, NJ, US, reflect accelerated depreciation, exit premiums, technology transfer costs, stability and qualification batch costs, and third-party contractor costs.
(3) Acquisition related costs for the three months ended March 31, 2026 and 2025, reflect the amortization pertaining to the fair value inventory purchase accounting adjustment for the Dermavant transaction.
As the costs described in (1) through (3) above are directly related to the separation of Organon and acquisition related activities and therefore arise from a one-time event outside of the ordinary course of the company’s operations, the adjustment of these items provides meaningful, supplemental, information that the company believes will enhance an investor's understanding of the company's ongoing operating performance.
Full text with the tables
Exhibit 99.1
Media Felicia Investor Jennifer
Contacts: Bisaro Contacts: Halchak
(646) (201) 275-2711
703-1807
Kate Renee
Vossen McKnight
(732) (551)
675-8448 204-6129
Organon Reports Results for the First Quarter Ended March 31, 2026
First quarter 2026
· revenue of $1.460 billion, down 4% as-reported and down 9% excluding the
impact of foreign
currency.
First quarter 2026
· diluted earnings per share of $0.55 and non-GAAP Adjusted diluted
earnings per share of $0.71.
First
· quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of
$415 million,
representing an Adjusted EBITDA margin of 28.4%.
On April 26,
2026, the company announced its pending merger into Sun Pharmaceutical
Industries Limited
(together with its subsidiaries and/or associated companies, “Sun
Pharma”) in
an all-cash transaction (the “merger”). The merger is expected to close
in early
2027, subject to customary closing conditions, including receipt of
required regulatory approvals
· and approval by Organon stockholders.
──────────────────────────────────────────────────────────────────────────────
In light of the pending
· merger, Organon will not be providing financial guidance or hosting
quarterly earnings calls.
Jersey City, N.J., April 30, 2026 – Organon (NYSE: OGN)
today announced its results for the first quarter ended March 31, 2026.
1
First Quarter 2026 Revenue
in $ VPY
millions Q1 2026 Q1 2025 VPY ex-FX
──────────────────────────────────────────────────────────────────────────────
Women’s $ 389 $ 463 (16 )% (19 )%
Health
General
Medicin…
Biosimi… 173 141 23 % 21 %
Establi… 880 887 (1 )% (7 )%
Brands
Other 18 22 (15 )% (21 )%
(1)
Revenue $ 1,460 $ 1,513 (4 )% (9 )%
Totals may not foot due to rounding and percentages are computed using unrounded
amounts.
(1) Other includes manufacturing sales to third parties.
For the first quarter of 2026, total revenue was $1.460 billion, down
4% on an as-reported basis and down 9% excluding the impact of foreign currency
(ex-FX), compared with the first quarter of 2025.
Women’s Health revenue declined 16% as-reported and declined
19% ex-FX in the first quarter of 2026, compared with the first quarter of 2025.
Sales of Nexplanon®
(etonogestrel implant) decreased 21% ex-FX in the first quarter compared
with the first
quarter of 2025. In the U.S., sales of Nexplanon declined 28% primarily
due to both
– decreased physician demand following the five-year label approval which
as expected, has
delayed reinsertions; and continued uncertainty around federal funding.
Outside of the U.S.,
Nexplanon sales declined 4% ex-FX, due to the timing of shipments in
selective emerging
markets, partially offset by increased demand and access in Brazil.
Sales of oral contraceptives MarvelonTM (desogestrel
and ethinyl estradiol pill) and MercilonTM (desogestrel and ethinyl
– estradiol
pill) declined 36% ex-FX in the first quarter of 2026 primarily due to
decreased demand and
market contraction in China and the timing of shipments in Asia Pacific.
Global Fertility revenue was down 9% ex-FX as a result of
– competition-driven
price reductions in the U.S. partially offset by modest market growth in
China.
– In January of 2026 the company completed the sale of the
Jada® system to Laborie.
2
Biosimilars revenue increased23% as-reported and 21% ex-FX in the first quarter
of 2026, compared with the first quarter of2025, primarily due to the strong
performance of Hadlima® (adalimumab-bwwd)
associated with stronger demand in the U.S., and increased demand in Puerto
Rico. Biosimilars also benefitted from contribution from
new assets, Bildyos® (denosumab-nxxp) and Bilprevda® (denosumab-nxxp) which were
approved by the U.S. Food and
Drug Administration (“FDA”) in the third quarter of 2025, and Tofidence®
(tocilizumab-bavi), which the company
acquired in the second quarter of 2025.
Established Brands revenue declined1% as-reportedand declined 7% ex-FX in the
first quarter of 2026.Revenue contribution from Emgality®(galcanezumab-gnlm)
partially offset
a decline in the respiratory portfolio, which was driven by pricing pressure, as
well as volume declines related to the adoption of revised
medical guidelines that deprioritize the use of montelukast, including
Singulair®(montelukast sodium), in various
international markets, most recently, in China. Global sales of
Dulera®(mometasone furoate and formoterol fumarate dihydrate)
also declined in the first quarter of 2026 primarily due to pricing pressure and
decreased demand in the U.S. VTAMA®(tapinarof)
grew modestly in the first quarter of 2026 compared with the first quarter of
2025.
(1) Organon acquired certain European licensing and distribution
rights to Emgalityfrom Eli Lilly and Company (“Eli Lilly”) beginning in early
2024. Emgalityis a registered
trademark of Eli Lilly in the European Union and other countries (used under
license).
3
First Quarter 2026 Profitability
in $ millions,
except per
share amounts Q1 2026 Q1 2025 VPY
──────────────────────────────────────────────────────────────────────────────
Revenues $ 1,460 $ 1,513 (4 )%
Cost of sales 677 672 1 %
Gross profit 783 841 (7 )%
Non-GAAP
Adjusted gross 861 934 (8 )%
profit (1)
Net income 146 87 68 %
Non-GAAP
Adjusted net 188 265 (29 )%
income (1)
Diluted Earnings 0.55 0.33 67 %
per Share (EPS)
Non-GAAP
Adjusted diluted 0.71 1.02 (30 )%
EPS (1)
Acquired
in-process
research & — 6 NM
development
(IPR&D)
and milestones
Adjusted
EBITDA (Non-GAAP) 415 484 (14 )%
(1)
Q1 Q1
2026 2025
Gross margin 53.6 % 55.6 %
Non-GAAP 59.0 % 61.7 %
Adjusted gross margin (1)
Adjusted 28.4 % 32.0 %
EBITDA margin (Non-GAAP) (1, 2)
(1) See Tables 4 and 5 for reconciliations of GAAP to non-GAAP financial
measures.
Reported gross margin in the first quarter of 2026 was 53.6% compared
with 55.6% in the prior year period. Non-GAAP Adjusted gross margin was 59.0% in
the first quarter of 2026, compared to 61.7% in the
first quarter of 2025. Unfavorable pricing and product mix as well as foreign
exchange rates were notable drivers in the decline of both
reported gross margin and non-GAAP Adjusted gross margin.
Net income for the first quarter of 2026 was $146 million, or $0.55
per diluted share, compared with net income of $87 million, or $0.33 per diluted
share, in the first quarter of 2025. For the first quarter
of 2026, non-GAAP Adjusted net income was $188 million, or $0.71 per diluted
share, compared with $265 million, or $1.02 per diluted
share, for the first quarter of 2025.
4
Non-GAAP Adjusted EBITDA margin was 28.4% in the first quarter of
2026 compared with 32.0% in the first quarter of 2025. The year-over-year
decline was primarily driven by a decrease in Adjusted Gross
Margin.
Capital Allocation
Today, Organon’s Board of Directors declared a quarterly dividend
of $0.02 for each issued and outstanding share of the company's common stock.
The dividend is payable on June 11, 2026, to
stockholders of record at the close of business on May 11, 2026.
As of March 31, 2026, cash and cash equivalents were $1.12 billion,
and debt was $8.57 billion.
Webcast Information
As is customary during the pendency of an acquisition, Organon has
suspended its quarterly earnings calls and will not host a conference call in
conjunction with today’s first quarter earnings release.
About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission
to deliver impactful medicines and solutions for a healthier every day. With a
portfolio of over 70 products across Women’s Health
and General Medicines, which includes biosimilars, Organon focuses on addressing
health needs that uniquely, disproportionately or differently
affect women, while expanding access to essential treatments in over 140
markets.
Headquartered in Jersey City, New Jersey, Organon is committed to
advancing access, affordability, and innovation in healthcare. Learn more at
http://www.organon.com and follow us on LinkedIn, Instagram,
X,YouTube, TikTok and Facebook.
5
Cautionary Note Regarding Non-GAAP Financial Measures
This press release contains “non-GAAP financial measures,”
which are financial measures that either exclude or include amounts that are
correspondingly not excluded or included in the most directly
comparable measures calculated and presented in accordance with U.S. generally
accepted accounting principles (“GAAP”). Specifically,
the company makes use of the non-GAAP financial measures Adjusted EBITDA,
Adjusted EBITDA margin, Adjusted gross margin, Adjusted gross
profit, Adjusted net income, Adjusted EPS, and Adjusted diluted EPS, which are
not recognized terms under GAAP and are presented only
as a supplement to the company’s GAAP financial statements. This press release
also provides certain measures that exclude the
impact of foreign exchange. We calculate foreign exchange by converting our
current-period local currency financial results using the
prior period average currency rates and comparing these adjusted amounts to our
current-period results. The company believes that these
non-GAAP financial measures help to enhance an understanding of the company’s
financial performance. However, the presentation
of these measures has limitations as an analytical tool and should not be
considered in isolation, or as a substitute for the company’s
results as reported under GAAP. Because not all companies use identical
calculations, the presentations of these non-GAAP measures may
not be comparable to other similarly titled measures of other companies. Please
refer to Table 4 and Table 5 of this press release for
additional information, including relevant definitions and reconciliations of
non-GAAP financial measures contained herein to the most
directly comparable GAAP measures.
The company’s management uses the non-GAAP financial measures
described above to evaluate the company’s performance and to guide operational
and financial decision making. Further, the company’s
management believes that these non-GAAP financial measures, which exclude
certain items, help to enhance its ability to meaningfully
communicate its underlying business performance, financial condition and results
of operations.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, this press release includes “forward-looking
statements” within the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, including,
but not limited to, statements relating to the merger, including the anticipated
timing of completion thereof. Forward-looking statements
may be identified by words such as “proposed,” “will,” “continue,” “expects,”
“believes,”
“estimates,” “opportunity,” “pursue,” “anticipate,” “be able to,” “intend,”
or words of similar meaning. These statements are based upon the current beliefs
and expectations of the company’s management and
are subject to significant risks and uncertainties. If underlying assumptions
prove inaccurate, or risks or uncertainties materialize,
actual results may differ materially from those set forth in the forward-looking
statements.
6
Risks and uncertainties include, but are not limited to uncertainties
as to the timing of the merger; the risk that the merger may not be completed on
the anticipated terms in a timely manner or at all;
the failure to satisfy any of the conditions to the consummation of the merger,
including receiving, on a timely basis or otherwise,
the minimum vote required by Organon’s stockholders to approve the merger; the
possibility that competing offers or acquisition
proposals for Organon will be made; the possibility that any or all of the
various conditions to the consummation of the merger may not
be satisfied or waived, including the failure to receive any required regulatory
approvals from any applicable governmental entities
(or any conditions, limitations or restrictions placed on such approvals); the
occurrence of any event, change or other circumstance
that could give rise to the termination of the definitive agreement, including
in circumstances which would require Organon to pay a
termination fee; the effect of the announcement or pendency of the merger on
Organon’s ability to retain and hire key personnel,
its ability to maintain relationships with its customers, suppliers and others
with whom it does business, or its operating results and
business generally; risks related to diverting management’s attention from
Organon’s ongoing business operations; the risk
that stockholder litigation in connection with the merger may result in
significant costs of defense, indemnification and liability;
certain restrictions during the pendency of the merger that may impact Organon’s
ability to pursue certain business opportunities
or strategic transactions; the risk that any announcements relating to the
merger could have adverse effects on the market price of Organon’s
common stock, including if the merger is not consummated; risks that the
benefits of the merger are not realized when and as expected;
and legislative, regulatory and economic developments.
The company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be found
in the company’s filings with the SEC, including
the company’s most recent Annual Report on Form 10-K, Current Report on Form
8-K, filed by the company on April 27,
2026, and other SEC filings, available at the SEC’s Internet site (www.sec.gov).
7
Additional Information and Where to Find It
This press release may be deemed to be solicitation material in respect
of the proposed merger. In connection with the merger, Organon intends to file
relevant materials with the SEC, including Organon’s
proxy statement in preliminary and definitive form on Schedule 14A (the “Merger
Proxy Statement”). Organon will mail the
Merger Proxy Statement and a proxy card to its stockholders in connection with
the merger.
INVESTORS AND STOCKHOLDERS OF ORGANON ARE URGED TO READ ALL RELEVANT
DOCUMENTS FILED WITH THE SEC, INCLUDING THE MERGER PROXY STATEMENT (WHEN THEY
ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN
IMPORTANT INFORMATION ABOUT ORGANON, SUN PHARMA AND THE MERGER AND RELATED
MATTERS. Investors and stockholders of Organon are or will
be able to obtain these documents (when they are available) free of charge from
the SEC’s website at , or through
the investor relations section of Organon’s website, .
Participants in the Solicitation
Organon and its directors, executive officers and other members of
management and employees, under SEC rules, may be deemed to be “participants” in
the solicitation of proxies from stockholders
of Organon in favor of the proposed acquisition. Information about Organon’s
directors and executive officers is set forth in the
2026 Annual Meeting Proxy Statement, filed with the SEC on April 24, 2026, and
which is available at .
To the extent holdings of Organon’s securities by its directors or executive
officers have changed since the amounts set forth
in the 2026 Annual Meeting Proxy Statement, such changes have been or will be
reflected on Initial Statements of Beneficial Ownership
on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC,
which are available at .
Additional information concerning the interests of Organon’s participants in the
solicitation, which may, in some cases, be different
than those of Organon’s stockholders generally, will be set forth in the Merger
Proxy Statement when it becomes available.
8
TABLE 1
Organon & Co.
Condensed Consolidated Statement of Income
(Unaudited, $ in millions except shares in thousands
and per share amounts)
Three Months
Ended
March 31, 2026 2025
──────────────────────────────────────────────────────────────────────────────
Revenues $ 1,460 $ 1,513
Cost of sales 677 672
Gross Profit 783 841
Selling, general and 424 420
administrative
Research and development 93 96
Acquired in-process research
and — 6
development and milestones
Restructuring costs 31 86
Interest expense 111 124
Exchange losses (gains) 7 (4 )
Other (income) expense, net (96 ) 12
Income before income taxes 213 101
Income tax expense 67 14
Net income $ 146 $ 87
Earnings per share:
Basic $ 0.56 $ 0.34
Diluted $ 0.55 $ 0.33
Weighted average shares
outstanding:
Basic 260,370 257,862
Diluted 262,896 261,001
TABLE 2
Organon & Co.
Sales by top products
(Unaudited, $ in millions)
Th…
Mo…
($ En…
in Ma…
m… 31,
W… 20… 20…
H… U.… In… To… U.… Int… Tot…
──────────────────────────────────────────────────────────────────────────────
N… $ 127 $ 74 $ 201 $ 176 $ 72 $ 248
N…
F… 21 39 61 35 34 69
AQ
N… 6 18 24 6 16 22
G…
A… 2 24 26 5 23 27
I…
M… — 26 26 — 39 39
J… 5 — 5 15 — 15
O…
W… 17 30 46 15 27 43
H…
(…
G…
M…
B…
R… 42 15 57 44 12 57
H… 51 16 67 33 14 47
O… 4 1 5 4 14 18
B… — 20 20 — 14 14
O…
B… 11 13 24 — 5 5
(…
E…
B…
C…
A… — 85 85 — 77 77
Z… 1 86 87 1 84 85
C… 2 55 57 2 53 55
V… 1 20 21 1 22 23
R… — 6 6 — 4 4
O…
C… 1 27 28 — 30 30
(…
R…
S… 2 38 40 2 72 74
N… — 65 65 — 71 72
D… 23 12 35 34 10 43
C… 1 30 31 — 34 34
O…
R… 11 1 12 10 3 13
(…
N…
P…
B…
a…
D…
A… — 59 59 — 62 62
F… — 29 29 1 32 33
D… — 35 35 — 30 30
V… 23 2 25 20 4 24
O…
N…
P…
B… 3 65 68 4 65 68
a…
D…
(…
O…
P… 1 28 30 1 24 26
E… — 54 54 — 32 32
P… — 26 26 — 24 24
O… 3 85 87 3 76 78
(…
O… — 18 18 — 22 22
(…
R… $ 358 $ 1,… $ 1,… $ 412 $ 1,… $ 1,…
Totals may not foot due to rounding. Trademarks appearing above in italics are
trademarks of, or are used under license by, the Organon group of companies.
(1) Includes sales of products not listed separately.
(2)Other includes manufacturing sales to third parties.
TABLE 3
Organon & Co.
Sales by geographic area
(Unaudited, $ in millions)
Three Months
Ended
March 31, 2026 2025
────────────────────────────────────────────────────────────────────────────
Europe and Canada $ 412 $ 376
United States 358 412
Asia Pacific and Japan 226 251
China 194 204
Latin America, Middle East, Russia, and 247 240
Africa
Other 23 30
(1)
Revenues $ 1,460 $ 1,513
(1) Other includes manufacturing sales to third parties.
TABLE 4
Organon & Co.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Metrics
(Unaudited, $ in millions)
Three Months
Ended
March 31, 2026 2025
─────────────────────────────────────────────────────────────────
GAAP Gross Profit $ 783 $ 841
Adjusted for:
Manufacturing 21 29
network costs (1)
Stock-based compensation 3 4
Amortization 47 50
Acquisition-related 7 9
costs (2)
Other — 1
Adjusted Non-GAAP Gross Profit $ 861 $ 934
(1) Manufacturing network related costs include costs from exiting manufacturing
and supply agreements with Merck & Co., Inc., Rahway NJ, US. For additional
details refer to Table 5. (2) Acquisition-related costs relate to costs from the
acquisition of Dermavant. For additional details refer to Table 5.
Three Months
Ended
March 31,
2026 2025
GAAP Gross Margin 53.6 % 55.6 %
Total impact of Non-GAAP 5.4 % 6.1 %
adjustments
Adjusted Non-GAAP Gross Margin 59.0 % 61.7 %
Three Months
Ended
March 31, 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP Selling, general $ 424 $ 420
and administrative expenses
Adjusted for:
Stock-based compensation (13 ) (16 )
Restructuring related charges — (6 )
Other (13 ) (3 )
Adjusted Non-GAAP Selling, general
and $ 398 $ 395
administrative expenses
TABLE 4
Organon & Co.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Metrics (Continued)
(Unaudited, $ in millions except per share amounts)
Three Months
Ended
March 31, 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP Research and $ 93 $ 96
development expenses
Adjusted for:
Manufacturing (3 ) (3 )
network costs (1)
Stock-based compensation (3 ) (4 )
Other (1 ) (1 )
Adjusted Non-GAAP Research and
development $ 86 $ 88
expenses
(1) Manufacturing network related costs include costs from exiting manufacturing
and supply agreements with Merck & Co., Inc., Rahway NJ, US. For additional
details refer to Table 5.
Three Months
Ended
March 31, 2026 2025
─────────────────────────────────────────────────────────────────────────────
GAAP Reported Net $ 146 $ 87
Income
Adjusted for:
Cost of sales adjustments 78 93
Selling, general and administrative 26 25
adjustments
Research and development adjustments 7 8
Jada divestiture (81 ) —
Restructuring 31 86
Change in fair value of contingent (5 ) 11
consideration
Other (gain) expense, net (3 ) 4
Tax (11 ) (49 )
impact on adjustments above(1)
Non-GAAP Adjusted Net Income $ 188 $ 265
(1) For the three months ended March 31, 2026 and 2025, the GAAP income tax
rates were 31.4% and 13.4%, respectively, and the non-GAAP income tax rates were
29.3% and 19.2%, respectively. These adjustments represent the estimated tax
impacts on the reconciling items by applying the statutory rate and applicable
law of the originating territory of the non-GAAP adjustments.
Three Months
Ended
March 31, 2026 2025
───────────────────────────────────────────────────────────────────────
GAAP Diluted Earnings per Share $ 0.55 $ 0.33
Total impact of Non-GAAP adjustments 0.16 0.69
Non-GAAP Adjusted Diluted Earnings $ 0.71 $ 1.02
per Share
TABLE 5
Organon & Co.
Reconciliation of GAAP Net (Loss) Income to Non-GAAP Adjusted EBITDA
(Unaudited, $ in millions)
Three Months
Ended
March 31, 2026 2025
───────────────────────────────────────────────────────────────────────────
GAAP Reported Net Income $ 146 $ 87
Depreciation 38 32
(1)
Amortization 47 50
Interest expense 111 124
Income tax expense 67 14
(benefit)
EBITDA (Non-GAAP) $ 409 $ 307
Restructuring and related charges 31 92
Manufacturing 27 36
network related (2)
Acquisition-related 7 9
costs (3)
Change in contingent consideration (5 ) 11
Jada divestiture (81 ) —
Other costs 8 5
Stock-based compensation 19 24
Adjusted EBITDA (Non-GAAP) $ 415 $ 484
Adjusted EBITDA margin (Non-GAAP) 28.4 % 32.0 %
(1) Excludes accelerated depreciation included in one-time costs.
(2) Manufacturing network related costs, including exiting of temporary
manufacturing and supply agreements with Merck & Co., Inc., Rahway, NJ, US,
reflect accelerated depreciation, exit premiums, technology transfer costs,
stability and qualification batch costs, and third-party contractor costs.
(3) Acquisition related costs for the three months ended March 31, 2026 and
2025, reflect the amortization pertaining to the fair value inventory purchase
accounting adjustment for the Dermavant transaction.
As the costs described in (1) through (3) above are directly related to the
separation of Organon and acquisition related activities and therefore arise
from a one-time event outside of the ordinary course of the company’s
operations, the adjustment of these items provides meaningful, supplemental,
information that the company believes will enhance an investor's understanding
of the company's ongoing operating performance.